Target intelligence / Profile preview

Lung

Molecular classification
Other
01

Overview

The lung is the primary organ of the respiratory system, facilitating the essential exchange of oxygen and carbon dioxide between the environment and the bloodstream [10]. It comprises a hierarchical structure of airways—trachea, bronchi, and bronchioles—that terminate in specialized air sacs called alveoli, where gas exchange occurs across a delicate epithelial-endothelial interface [7, 10]. The lung is not a singular molecular target; rather, it is a tissue environment containing diverse cell types (such as pneumocytes, macrophages, and endothelial cells) and numerous specific molecular targets like G protein-coupled receptors, ion channels, and tyrosine kinases [5, 7, 12]. In the context of drug development, the lung is the site of pathology for major conditions including asthma, chronic obstructive pulmonary disease (COPD), and lung cancer, which are treated by targeting specific proteins within the pulmonary architecture [1, 2, 4]. Therapeutic agents are often delivered via inhalation to achieve high local concentrations at the site of disease while reducing systemic exposure and potential side effects [5]. Consequently, while the lung is the focus of many therapies, it is considered an organ/tissue system rather than a discrete target molecule [5, 10].

Other names
Pulmonary organRespiratory organ
02

Mechanism of action

Not applicable; the lung is a complex organ containing various molecular targets (receptors, enzymes, etc.) rather than being a single therapeutic target itself.

03

Biological functions

Gas exchangeRespirationAcid-base balanceImmune defenseMetabolism of xenobiotics
04

Disease associations

Lung cancerChronic obstructive pulmonary disease (COPD)AsthmaPneumoniaCystic fibrosisPulmonary fibrosis
05

Safety considerations

Pulmonary toxicityDrug-induced pneumonitisBronchospasmRespiratory depression
06

Biomarkers

Surfactant protein D (SP-D)KL-6 (Krebs von den Lungen-6)Carcinoembryonic antigen (CEA)CYFRA 21-1 (Cytokeratin 19 fragment)

Beyond the preview

Go deeper on Lung.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lung.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call